Proven respiratory recruitment, built for severe, uncontrolled asthma. We find the high-intent patients others miss, across digital, advocacy, and community channels, in any language.

Leapcure has recruited across respiratory and complex disease, including a global Phase 2 pulmonary program. For severe asthma, we reach the right patients across digital, advocacy, and community channels in their own language, and pre-screen rigorously so your sites receive ready candidates.

Talk to our teamSee how it works →
8,873
Pre-screened
on a Phase 2 respiratory program
50+
Countries reached
across our programs
12,000+
Global advocacy partnerships
including respiratory communities
130+
Studies recruited
across complex disease

Understanding Severe Asthma as a Clinical Trial Indication

Asthma is one of the most common chronic diseases. More than 25 million people in the US have asthma, with adult current-asthma prevalence around 8.6 percent in 2024 (CDC). About 60 percent of adults with current asthma have uncontrolled asthma (CDC). Within that, the severe, biologic-eligible segment is small, and it is the hard-to-find target for severe-asthma trials. Severe, uncontrolled asthma typically means disease that remains poorly controlled despite high-dose inhaled corticosteroids and maintenance therapy, often with a history of exacerbations and, increasingly, prior biologic use.

This is what makes severe asthma difficult to recruit: the eligible patients are a narrow slice hidden inside a very large asthma population, so generic, high-volume campaigns surface mild or well-controlled patients who then fail eligibility. Asthma also does not fall evenly. Per the CDC (2024), current asthma prevalence is higher among non-Hispanic Black adults (10.6 percent) and children (12.5 percent) than White adults (8.2 percent) and children (5.7 percent), and Puerto Ricans have the highest rate of any group, about 14 percent. Asthma causes more than 3,500 deaths a year in the US, concentrated in these same communities, which makes representation in severe-asthma trials both an equity and a label-breadth issue.

Leapcure recruits for severe asthma by finding the high-intent patients who are hardest to find and reaching them where they already are, across targeted digital, asthma advocacy communities, and condition-specific groups, in their own language. Our respiratory track record includes a global Phase 2 pulmonary program where we pre-screened nearly 9,000 patients and delivered enrollment-ready candidates across seven countries, and our experience spans both asthma and COPD. Our rigorous pre-screening combines technology with real human conversations to match candidates to complex severe-asthma eligibility before any site referral, so sites receive ready, motivated candidates rather than referral volume.

The Challenge

Severe asthma is hard to recruit because the eligible patients are a narrow segment hidden inside a very large asthma population, with complex criteria, dispersed across regions and languages, and concentrated in communities standard outreach misses.

The eligible segment is narrow inside a huge population

More than 25 million people in the US have asthma, but only the severe, uncontrolled, biologic-eligible slice fits most trials. Generic, high-volume campaigns surface mild or well-controlled patients who fail eligibility, spending site time on people the protocol cannot use. Finding the right patients takes targeting, not volume.

On a global Phase 2 pulmonary program, Leapcure contacted about 15,600 patients and pre-screened about 8,900 with real human engagement, not just digital clicks.

Severe-asthma eligibility is complex

Protocols screen on uncontrolled disease despite high-dose inhaled corticosteroids and maintenance therapy, exacerbation history, and increasingly prior biologic use. Confirming that fit before referral is what protects coordinator time and reduces screen fails.

Technology plus real human conversations match candidates to specific severe-asthma eligibility before any site referral.

Patients are dispersed across regions and languages

Severe-asthma patients are spread across geographies and speak many languages, and trials increasingly enroll globally. Translation alone does not build trust. Reaching patients in their own language, with culturally adapted content, is what drives enrollment.

On a global Phase 2 pulmonary program, Leapcure delivered enrollment-ready candidates across seven countries, with about 49% of US enrollments and about 40% of enrollments outside the US.

Asthma falls hardest on communities trials miss

Current asthma prevalence is higher among non-Hispanic Black and Puerto Rican populations, and asthma deaths concentrate in these same communities (CDC, 2024). When severe-asthma trials underrepresent them, both equity and label breadth are at risk. Closing that gap takes a model built to reach them.

Our advocacy, community, and multilingual model is built to reach the Black, Puerto Rican, and low-income communities asthma hits hardest.

How Leapcure recruits for your severe-asthma study

We reach the right patients across digital, advocacy, and community channels in their own language, pre-screen rigorously for complex eligibility, and optimize across regions as sites engage.

1

Reach the high-intent segment across channels and languages

We deploy targeted digital across search and social, asthma and COPD advocacy communities, and condition-specific groups, with campaigns localized across languages such as German, Spanish, and Italian. Native-speaking patient advocates provide local, trusted communication, because localization goes beyond translation.

2

Pre-screen rigorously before any site referral

Technology plus real human conversations identify candidates who meet specific severe-asthma eligibility, including uncontrolled disease despite high-dose inhaled corticosteroids and maintenance therapy, exacerbation history, and prior biologic use. Sites conduct official screening; we make sure the candidates who arrive are ready and motivated.

3

Optimize across regions and languages as sites engage

We track channel and language performance and site contact rates in real time, and rebalance digital, advocacy, and community outreach by referral quality and site capacity. This keeps referrals matched to where sites can screen across every market in your study.

Our respiratory track record: a global Phase 2 pulmonary program where we pre-screened nearly 9,000 patients across seven countries.

Challenge Context

Program

A global Phase 2 pulmonary program (respiratory; labeled as pulmonary, not asthma)

Challenge

Finding eligible respiratory patients across seven countries and many languages, then delivering candidates ready for complex protocol screening.

Channels Deployed

Targeted digital across search and social, asthma and COPD advocacy communities, multilingual and culturally adapted campaigns, and rigorous human plus technology pre-screening.

Results & Metrics

Reach and Pre-screening

About 15,600 patients contacted and about 8,900 pre-screened for eligibility and interest, with real human engagement, not just digital clicks.

Site Delivery

About 360 patients assigned to sites and 50+ enrolled, with roughly 49 percent of US enrollments and about 40 percent of enrollments outside the US, across seven countries.

Site Penetration

72 percent of sites enrolled at least one Leapcure patient, and about a third of US sites relied exclusively on Leapcure referrals.

Search Visibility

Outperformed specialized competitors in respiratory search visibility, with about a 26 percent search impression share and about a 69 percent top-of-page rate, feeding the referral pipeline directly.

Four channels. Built for severe asthma. Active before your trial opens.

Leapcure reaches severe-asthma patients through deep asthma and COPD communities, global and multilingual outreach, rigorous pre-screening, and answer-engine and search visibility delivered to your trial.

Channel 1: Asthma and COPD community and advocacy network

  • •Global advocacy partners include the Respiratory Health Association, the American Lung Association, the Breathe Support Network, and the One Breath Foundation.
  • •We engage these communities from national patient organizations to grassroots caregiver and condition-specific groups, reaching patients traditional outreach misses.
  • •Our respiratory experience spans both asthma and COPD, so we reach patients across obstructive airway disease, not asthma alone.

Channel 2: Global, multilingual localization

  • •Campaigns localized across languages such as German, Spanish, and Italian, with culturally adapted content rather than translation alone.
  • •Native-speaking patient advocates provide local, trusted communication that builds trust and drives higher enrollment.
  • •Real-time optimization across languages and regions keeps reach matched to where your sites can screen.

Channel 3: Rigorous pre-screening

  • •Technology plus real human conversations identify candidates who meet specific severe-asthma eligibility before any site referral.
  • •We confirm uncontrolled disease despite high-dose inhaled corticosteroids and maintenance therapy, exacerbation history, and prior biologic use.
  • •Sites receive ready, motivated candidates, which protects coordinator time and reduces screen fails.

Channel 4: Answer-engine and search visibility

  • •Targeted ads across Facebook, Instagram, and Google reach adults and adolescents 12 and older with severe, uncontrolled asthma at the moment they search for options beyond their current treatment.
  • •We make your trial's information genuinely retrievable for AI engines like ChatGPT, Perplexity, and Google's AI Overview, through crawlable, factually rich content, cited sources, and presence in trusted communities, not schema tricks or content written for machines.
  • •We also outperform specialized competitors in respiratory search visibility, and because AI engines cite trusted third-party sources more often than any single brand domain, our advocacy partnerships and ClinicalTrials.gov presence are the structural advantage we bring to your trial.

Built on deep asthma and respiratory communities

Leapcure's respiratory advocacy partnerships are active and co-developed, not list purchases, spanning national patient organizations and grassroots caregiver and condition-specific groups across regions.

Respiratory Health Association

National respiratory-health organization reaching asthma and lung-disease patients and caregivers

American Lung Association

Leading US lung-health organization with broad reach across the asthma community

Breathe Support Network

Patient and caregiver support community for people living with respiratory disease

One Breath Foundation

Respiratory-focused patient organization extending reach into asthma communities

Grassroots and community groups

Caregiver, condition-specific, and trusted community voices across regions, including multilingual communities

Living with severe, uncontrolled asthma? A clinical trial may be an option to explore.

If you are an adult or adolescent (12 and older) living with severe, uncontrolled asthma, or a caregiver of a child with asthma, a clinical trial may offer access to investigational treatments alongside your existing asthma care, never instead of it. Leapcure's team answers your questions in your own language, explains what a trial involves, and supports you step by step, with no pressure.

See if a severe-asthma trial may be right for you
Leapcure kangaroo mascot

Leapcure is built for severe asthma: proven respiratory recruitment, including a global Phase 2 pulmonary program that pre-screened nearly 9,000 patients across seven countries, plus deep asthma and COPD communities, global and multilingual reach, and rigorous pre-screening that finds the narrow eligible segment and protects site time. We reach the high-intent patients others miss and deliver ready candidates to your sites. We can mobilize quickly.

Talk to our team